Table 6.

Multivariate Cox regression analysis A) for HER2/TOP2A co-amplification, B) for HER2/TOP2A mRNA expression, C) for HER2/TopoIIa protein expression and D) for all combined HER2/TOP2A parameters, adjusted for significant clinicopathological parameters in terms of DFS and OS

		Disease-free survival			Overall survival
		HR	95% C.I.	Wald's p	HR	95% C.I.	Wald's p
A)	E-CMF vs E-T-CMF	1.26	0.85-1.88	0.25	1.67	1.03-1.72	0.038
	Nodal involvement (≥ 4 vs 0-3)	3.53	1.82-6.85	< 0.001	2.96	2.96	0.004
	Hormone receptor status (pos. vs neg.)	0.48	0.31-0.77	0.002	0.40	0.24-0.68	0.018
	Ki-67 (high vs low)	1.97	1.06-3.65	0.031	2.77	1.19-6.46	0.018
	HER2&TOP2A gene (both ampl. vs all other)	0.12	0.02-0.88	0.037	0.16	0.02-1.14	0.067
B)	E-CMF vs E-T-CMF	1.16	0.77-1.75	0.47	1.56	0.95-2.57	0.079
	Nodal involvement (≥ 4 vs 0-3)	2.67	1.44-4.93	0.002	2.07	1.05-4.09	0.035
	Hormone receptor status (pos. vs neg.)	0.57	0.36-0.91	0.018	0.48	0.28-0.83	0.008
	Ki67 (high vs low)	1.92	0.98-3.77	0.057	3.40	1.22-9.48	0.019
	HER2&TOP2A mRNA (high vs low)	2.30	1.39-3.81	0.001	2.48	1.41-4.36	0.002
C)	E-CMF vs E-T-CMF	1.18	0.80-1.74	0.39	1.62	1.02-2.57	0.042
	Nodal involvement (≥ 4 vs 0-3)	3.00	1.64-5.49	< 0.001	2.43	1.25-4.73	0.009
	Hormone receptor status (pos. vs neg.)	0.64	0.41-0.99	0.047	0.51	0.31-0.85	0.009
	Ki67 (high vs low)	1.68	0.93-3.05	0.086	2.27	1.03-5.00	0.041
	HER2&TopoIIa IHC (both pos. vs all other)	1.77	1.04-3.05	0.034	1.58	0.86-2.91	0.14
D)	E-CMF vs E-T-CMF	1.13	0.73-1.75	0.59	1.53	0.89-2.26	0.12
	Nodal involvement (≥ 4 vs 0-3)	3.62	1.78-7.34	< 0.001	2.87	1.29-6.40	0.010
	Hormone receptor status (pos. vs neg.)	0.51	0.31-0.84	0.009	0.45	0.25-0.81	0.008
	Ki67 (high vs low)	2.05	0.99-4.21	0.051	4.35	1.34-14.18	0.015
	HER2&TOP2A gene (both ampl. vs all other)	0.13	0.02-0.96	0.046	0.23	0.03-1.74	0.15
	HER2&TOP2A mRNA (high vs low)	2.41	1.31-4.42	0.005	2.83	1.42-5.63	0.003
	HER2&TopoIIa IHC (both pos. vs all other)	1.36	0.68-2.70	0.38	0.92	0.42-2.18	0.92